跳至內容

CEBPD

本頁使用了標題或全文手工轉換
本頁使用了標題或全文手工轉換
維基百科,自由的百科全書
CEBPD
識別號
別名CEBPD;, C/EBP-delta, CELF, CRP3, NF-IL6-beta, CCAAT/enhancer binding protein delta, CCAAT enhancer binding protein delta
外部IDOMIM116898 MGI103573 HomoloGene3808 GeneCardsCEBPD
基因位置(人類
8號染色體
染色體8號染色體[1]
8號染色體
CEBPD的基因位置
CEBPD的基因位置
基因座8q11.21起始47,736,913 bp[1]
終止47,738,164 bp[1]
直系同源
物種人類小鼠
Entrez
Ensembl
UniProt
mRNA​序列

NM_005195

NM_007679

蛋白序列

NP_005186

NP_031705

基因位置​(UCSC)Chr 8: 47.74 – 47.74 MbChr 16: 15.71 – 15.71 Mb
PubMed​查找[3][4]
維基數據
檢視/編輯人類檢視/編輯小鼠

CCAAT/增強子結合蛋白δ,簡稱C/EBP-δCEBPD,是一種在人類中由CEBPD基因編碼的蛋白質[5][6]

功能

[編輯]

由這種無內含子基因編碼的蛋白質是一種bZIP轉錄因子,它可以作為同源二聚體與某些DNA調節區結合。它還可以與相關蛋白C/EBP-α形成異二聚體。編碼的蛋白質在調節參與免疫炎症反應的基因中很重要,並且可能參與調節與巨噬細胞活化和/或分化相關的基因。[7]

CEBPD參與細胞凋亡細胞增殖的調節。它可能充當腫瘤抑制因子[8]

一項針對小鼠的研究表明,CEBPD在慢性阻塞性腎病進展過程中可防止腎小管損傷和腎小管間質纖維化的發展。[9]

CEBPD基因的功能可以通過基於獨立驗證的siRNA敲低來有效檢查。[10]

相互作用

[編輯]

CEBPD已被證明能與SMAD3相互作用。[11]

參見

[編輯]

參考文獻

[編輯]
  1. ^ 1.0 1.1 1.2 GRCh38: Ensembl release 89: ENSG00000221869 - Ensembl, May 2017
  2. ^ 2.0 2.1 2.2 GRCm38: Ensembl release 89: ENSMUSG00000071637 - Ensembl, May 2017
  3. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  4. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes & Development. Sep 1991, 5 (9): 1538–52. PMID 1840554. doi:10.1101/gad.5.9.1538可免費查閱. 
  6. ^ Williams SC, Cantwell CA, Johnson PF. A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes & Development. Sep 1991, 5 (9): 1553–67. PMID 1884998. doi:10.1101/gad.5.9.1553可免費查閱. 
  7. ^ Entrez Gene: CEBPD CCAAT/enhancer binding protein (C/EBP), delta. 
  8. ^ Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. Feb 2005, 24 (9): 1589–97. PMID 15674331. doi:10.1038/sj.onc.1208393可免費查閱. 
  9. ^ Duitman J, Borensztajn KS, Pulskens WP, Leemans JC, Florquin S, Spek CA. CCAAT-enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Laboratory Investigation; A Journal of Technical Methods and Pathology. Jan 2014, 94 (1): 89–97. PMID 24247561. doi:10.1038/labinvest.2013.127可免費查閱. 
  10. ^ Munkácsy, Gyöngyi; Sztupinszki, Zsófia; Herman, Péter; Bán, Bence; Pénzváltó, Zsófia; Szarvas, Nóra; Győrffy, Balázs. Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments. Molecular Therapy: Nucleic Acids. 2016, 5 (9): e366. ISSN 2162-2531. PMC 5056990可免費查閱. PMID 27673562. doi:10.1038/mtna.2016.66 (英語). 
  11. ^ Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. The Journal of Biological Chemistry. Mar 2003, 278 (11): 9609–19. PMID 12524424. doi:10.1074/jbc.M212259200可免費查閱. 

閱讀

[編輯]

外部連結

[編輯]